Investors looking for an exciting clinical-stage biotech start-up with enormous potential should be paying close attention to Recursion Pharmaceuticals (NASDAQ: RXRX). The company has emerged as a ...
The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $7.47, reflecting a -1.32% shift from the previouse trading day's closing. This move lagged the S&P 500's daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback